Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of epilepsy and seizure disorders
3.2.1.2 Development of novel rescue medications
3.2.1.3 Advances in non-invasive drug delivery systems
3.2.2 Industry pitfalls & challenges
3.2.2.1 Limited awareness and diagnosis
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 USL-261
5.3 Diastat Rectal Gel (DRG)
5.4 NRL-1
5.5 Other products
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Intranasal
6.3 Rectal
6.4 Oral
6.5 Other routes of administration
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
Chapter 9 Company Profiles
9.1 AdvaCare Pharma Limited
9.2 Aquestive Therapeutics
9.3 Bausch Health Companies
9.4 Lupin Limited
9.5 Neuracle Lifesciences
9.6 Neurelis
9.7 Pfizer
9.8 Sanofi
9.9 Takeda Pharmaceutical Company Limited
9.10 Teva Pharmaceutical Industries
9.11 UCB S.A.
9.12 Veriton Pharma
